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Abstract
Amyloidosis  is  a  generic  term that  refers  to a  wide spectrum of  diseases that  are
characterized  by  the  deposition  of  proteins  in  different  organs,  forming  insoluble
aggregates.  Examples  include  islet  amyloid  polypeptide  (IAPP)  associated  with
diabetes type 2, prion protein (PrP) related with spongiform encephalopathies, (TTR)
associated with familial amyloidotic polyneuropathy (FAP), and amyloid-beta (Aβ)
peptide linked to Alzheimer’s disease (AD), the most common form of dementia. Aβ
peptide, thought to be the causative agent in AD, is generated upon sequential cleavage
of  the amyloid precursor  protein (APP),  by beta-  and gamma-secretases,  and it  is
believed  that  an  imbalance  between  Aβ  production  and  clearance  results  in  its
accumulation in the brain. TTR is a 55 kDa homotetrameric protein synthesized by the
liver  and choroid plexus  of  the  brain  and is  involved in  the  transport  of  thyroid
hormones and retinol. TTR protects against Aβ toxicity by binding the peptide, thus
inhibiting its aggregation. Also, increased Aβ levels are found in both brain and plasma
of AD mice with only one copy of the TTR gene, when compared to animals with two
copies of the gene, suggesting a role for TTR in Aβ clearance. Growing evidence also
suggests a wider role for TTR in central nervous system neuroprotection, including in
the cases of ischemia, regeneration, and memory.
Keywords: Alzheimer’s disease (AD), Aβ peptide, transthyretin (TTR), neuroprotec‐
tion, blood–brain barrier (BBB)
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1. Amyloidosis
1.1. Amyloidosis definition
Amyloidosis has long been used as a general term referring to a wide spectrum of protein-
misfolding diseases  [1],  which are  characterized by the extracellular  deposition of  those
proteins in different organs, consequently forming insoluble aggregates called amyloid, a term
popularized  by  Virchow in  1854  [2].  According  to  the  Nomenclature  Committee  of  the
International Society of Amyloidosis (ISA), 31 identified proteins form extracellular amyloid
fibrils  in  humans  [3].  Amyloid  fibrils  are  characterized  by  certain  tinctorial  properties,
independently of the precursor protein forming the deposits, that for a long time were the only
diagnosis  available.  These  include  apple-green  birefringence  under  polarized  light  after
staining with Congo red and yellow-green fluorescence after staining with thioflavin S and
thioflavin T; thioflavin T has also been shown to interact with amyloid in suspension produc‐
ing a specific fluorescent signal with a new excitation maximum at 450 nm. Ultrastructural
studies by transmission electron microscopy (TEM) revealed that the amyloid material is
fibrillary appearing as bundles of straight or coiled fibrils, non-branched, 7–10 nm wide and
variable in length; in most cases, they seem to be helically twisted. Amyloid fibrils present a
high content in β-pleated sheet as demonstrated by x-ray diffraction analysis and extensive
antiparallel β-sheet strands with their axes running perpendicularly to the axis of the growing
fibril (cross-β pattern).
Amyloid deposits are not entirely composed of the amyloid precursor protein. Several
components have been found associated with all amyloid fibrils. These include serum amyloid
P component (SAP), sulphonated glycosaminoglycans (GAGs), apoliproteins E and J, α1-
antichymiotrypsin, several basement membrane components such as fibronectin, laminin and
collagen type IV, complement proteins, and metal ions.
The extracellular deposition of fibrillary proteins leads to cell damage, organ dysfunction and
death, and thus, these proteins are associated with a unique clinical syndrome, as seen in the
case of the islet amyloid polypeptide (IAPP) associated with diabetes type 2 [4], prion protein
(PrP) associated with the spongiform encephalopathies [5], transthyretin (TTR) associated with
familial amyloidotic polyneuropathy [6] (FAP), and amyloid-beta (Aβ) peptide associated with
Alzheimer’s disease [7] (AD), among others.
Amyloid disorders are usually divided into two categories depending on the distribution of
the amyloid deposits: localized and systemic amyloidosis. In localized amyloidosis, amyloid
is restricted to a single tissue or organ, usually in the surroundings of the cells responsible for
the synthesis of the precursor protein; in systemic amyloidosis, the amyloidogenic proteins
are usually derived from circulating precursors that are either in excess, abnormal or both.
Amyloidosis can also be hereditary or non-hereditary.
This chapter will focus in AD, a form of localized amyloidosis affecting the central nervous
system, and the most common form of dementia. In particularly, we will discuss the neuro‐
protective role of TTR in AD, in addition to its amyloidogenic role in FAP, an example of
systemic amyloidosis with a special involvement of the peripheral nerve.
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2. Overview of AD
AD was firstly described by Alois Alzheimer in 1906 and is characterized by progressive loss
of cognitive functions, ultimately leading to death [8]. This condition highly affects not only
the life of patients but also the life of their caregivers. Pathologically, the disease is character‐
ized by the presence of extraneuronal amyloid plaques consisting of aggregates of the Aβ
peptide, and neurofibrillary tangles (NFTs) which are intracellular aggregates of abnormally
hyperphosphorylated tau protein [9]. Aβ peptide is generated upon sequential cleavage of the
amyloid precursor protein (APP), by beta- and gamma-secretases, and it is believed that an
imbalance between Aβ production and clearance results in its accumulation in the brain.
2.1. From the first description to the confirmation
Alzheimer’s disease was first described in the 1907’s paper entitled “Uber eine eigenartige
Erkankung der Hirnrinde,“ by Alois Alzheimer [10], in which he reported the behavior of a
51-year-old female patient (Auguste Deter) of the insane asylum of Frankfurt am Main. The
patient presented several symptoms that caught Alzheimer’s attention, apart from the central
nervous system anatomical characteristics. Among others, time and space disorientation, rapid
loss of memory, and mood swings were the most prominent symptoms [10]. In relation to
pathological features, the observation of something that looked like “thick bundles” [10] of
fibrils, later known as senile/amyloid plaques and NFTs [11], transformed AD into a unique
condition, distinguishing it from the other neurological conditions known to date.
2.1.1. Symptoms and Diagnosis
Since 1907, clinicians have been trying their best to accurately identify AD-related symptoms
and to divide and organize these symptoms in the simplest form. Burns et al. came out in 2002
with three different categories: (1) cognitive deficits that affect memory (amnesia and agnosia),
speech (aphasia), and motor behavior; (2) psychiatric symptoms and behavioral disturbances,
including depression, anxiety, delusions, and misidentification; (3) difficulties with the daily
living activities, such as driving, using the telephone, dealing with money and, later in the
disease, all the basic needs (feeding, dressing, toileting) [12–14]. As expected in such a complex
condition, a huge symptomatic variation is found in AD patients, although a positive corre‐
lation between symptom severity and disease evolution is observed.
Although AD is seen as an elderly disease due to its higher prevalence in the older population
(approximately 5.3 million people solely in the US, in 2015) [15], it is also the most frequent
form of dementia under the age of 65, with up to 5% of all cases [16]. Of curiosity, every 67 s,
one more person is diagnosed with AD, and, by 2050, one new case of AD is expected to
develop every 33 s [15]. Due to this disease complexity, diagnosis guidelines had to be
established, and for a long time, the main criteria adopted was the one decided at the 1984
consortium, by the National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS–ADRDA).
These criteria divided AD in three possible diagnosis scenarios, which were possible, probable,
or definite AD [17]. More recently, some minor alterations have been proposed in order to
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comprise also the stages prior to the clinical observation of symptoms [18, 19], thus prompting
three renewed stages: (1) preclinical Alzheimer’s disease; (2) mild cognitive impairment (MCI)
due to Alzheimer’s disease; and (3) dementia due to Alzheimer’s disease [20].
Despite all the attentions directed to the establishment of proper diagnostic criteria and
guidelines available, the diagnosis of AD is still not an easy task. Actually, a recent meta-
analysis showed that the sensitivity and specificity of the clinical diagnosis ranged from 53 to
99% and 55 to 99%, respectively [21]. Although alone it is considered a low value, when
combined with other characterizing techniques (as neuroimaging and biomarkers—see
Biomarkers section), it is possible to predict/diagnose AD with a high confidence.
Genetically, AD is usually divided in two forms: autosomal dominant familial AD (FAD;
predominantly of early-onset—under the age of 65) and sporadic AD (also called and usually
associated to the late-onset AD—more than 65 years) [22]. Although extensively used, it is
important to point out that this classification is far too simplistic.
Despite all of the effort put into research, the primary event triggering AD remains yet a
mystery. Nonetheless, for FAD, several mutations capable of triggering the disease have been
identified, especially in three distinct genes: the amyloid precursor protein (APP) [23], the
presenilin 1 (PSEN1), and the presenilin 2 (PSEN2) genes [24], in chromosomes 21q, 14q, and
1q, respectively. Although these three genes comprise approximately 55% of all mutations,
they are only responsible for less than 1% of all cases of AD (http://www.molgen.vib-ua.be/
ADMutations/). Contrary to FAD, sporadic AD does not exhibit autosomal-dominant inheri‐
tance but up to 60–80% of this form of AD is genetically determined [22].
2.2. The biochemical basis of AD
In spite of its multifactorial etiology, AD is characterized by two specific brain lesions, the
amyloid plaques, and the NFTs, considered the hallmarks of AD. Also, associated with these
abnormalities, it is often observed severe neural loss and reactive gliosis.
NFTs are filamentous inclusions (intracellular lesions), preferentially observed in pyramidal
neurons, which are composed of filamentous aggregates of abnormally hyperphosphorylated
microtubule-associated protein tau [25]. Even though NFTs are a hallmark of AD, they are also
observed for other neurodegenerative disorders termed tauopathies (e.g., sporadic cortico‐
basal degeneration, palsy, and Pick’s disease, progressive supranuclear palsy, Seattle family
A, parkinsonism–dementia complex of Guam, and some frontotemporal dementias) [26, 27].
As for amyloid plaques, they can be distinguished in different plaques subtypes, depending
on their composition, and being the neuritic and diffuse plaques the two major subtypes in
AD. Neuritic plaques are constituted by the 40- and 42-amino acids (aa) Aβ peptides [28] (Aβ40
and Aβ42, respectively), surrounded by dystrophic neurites (axons and dendrites), microglia
(monocyte- or macrophage-derived cells that reside in the brain), and reactive astrocytes [29].
Diffuse deposits are mainly composed of Aβ42 [28] and lack the neuritic and glial components
[29], but evolve over time with formation of discrete niduses that eventually become neuritic
amyloid plaques [30].
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2.3. Amyloid-β precursor protein and Aβ formation
The amyloid-β precursor protein (APP) is a transmembrane receptor expressed ubiquitously
in both neuronal cells and extra-neuronal tissues [31]. In humans, the APP gene is located in
the chromosome 21, explaining partially the increased risk for Down syndrome patients to
develop AD, and is composed of 18 exons [32]. Three major isoforms are expressed by
alternative splicing: APP770 (full length), APP751 (lacking exon 8), and APP695 (lacking exon
7 and exon 8) [23, 31, 33]. APP belongs to a highly conserved family of type 1 transmembrane
glycoproteins that extends also to invertebrate species, including the homologous: APL-1
(Caenorhabditis elegans), APPL (Drosophila), APLP1, and APLP2 (in mammals, besides APP)
[34], and appa and appb (zebrafish) [35]. Following translation, APP is trafficked through the
endoplasmic reticulum (ER), Golgi and trans-Golgi network (TGN), where it suffers specific
endoproteolytic cleavages [33] that will originate several APP metabolites, among them the
Aβ peptide. After reaching the membrane surface, APP can still undergo clathrin-mediated
endocytosis and then be recycled to the surface again [36], during which Aβ can also be
produced [37].
The 4 kDa Aβ peptide was first isolated and sequenced by Glenner and Wong, in 1984 [7] and
can be found in the plasma and cerebrospinal fluid (CSF) of healthy humans and other
mammals [38]. It was described as a 24 aa peptide but later, sequencing analysis revealed that
the peptide could actually comprise 36–43 aa [39], being the two major species Aβ40 and Aβ42.
In healthy individuals, these two forms make up about 90 and 10%, respectively, of the Aβ
peptides that are normally produced by brain cells [40]. Despite the small difference in size
and sequence of the various isoforms, they differ greatly in properties; for example, Aβ42 is
more hydrophobic, thus, more prone to aggregation (compared to the less hydrophobic Aβ40).
In fact, it readily aggregates in vitro, being considered the more amyloidogenic and hence
pathogenic species [41].
2.3.1. Towards amyloid or not?
APP processing can originate different metabolites that bear very different physiological
functions, depending on the proteolysis pathway adopted: the amyloidogenic or non-
amyloidogenic pathway (Figure 1). In the non-amyloidogenic pathway, APP is firstly cleaved
by the α-secretase, a zinc metalloproteinase of the ADAM family [42], followed by the action
of γ-secretase. The latter is a high molecular weight complex of four proteins: presenilin 1 or
2 (PSEN1, PSEN2), nicastrin (NCT) [43, 44], anterior pharynx-defective 1 (APH1), and prese‐
nilin enhancer 2 (PEN2) [45]. The cleavage by the α-secretase (at Lys687 of APP770) [46], within
the Aβ domain, abrogates the production of Aβ, resulting in the release of a large soluble
ectodomain of APP (sAPPα, ~100 kDa), leaving behind a 83-residue carboxi-terminal fragment
(CTFα, of ~10 kDa) [47]. Then, γ-secretase cuts the CTFα, liberating the extracellular p3 peptide
and the 50 aa APP intracellular domain (AICD, of ~6 kDa) [48].
On the other hand, as suggested by its name, the amyloidogenic pathway gives rise to the
amyloidogenic Aβ peptide, and similar to the previous pathway, it consists of two sequential
cleavages, first by the β-secretase (beta-site APP–cleaving enzyme 1–BACE-1), and then by γ-
secretase. The first protease cleaves APP at Met671 [49], releasing the large soluble ectodomain
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sAPPβ [33]. The remaining 99 aa CTFβ (of ~12 kDa) [50] is then cleaved by the γ-secretase, in
the membrane, and originates, as said above, the Aβ peptide and the AICD [48]. This process
generates different Aβ species, with variable hydrophobic C-termini (related to the γ-secretase
cleaving site), that present different propensity to oligomerize [51] and, consequently, to form
the amyloid plaques. Noteworthy, AD-linked mutations in the PSEN1 and PSEN2 proteins,
particularly important in the case of FAD, influence γ-secretase-mediated processing of APP,
and selectively enhance Aβ42 production compared to Aβ40 [52].
Figure 1. The amyloidogenic and non-amyloidogenic pathways of APP. In the non-amyloidogenic pathway, APP is
cleaved by the α-secretase releasing the sAPPα neuroprotective N-terminal fragment, which contains part of the Aβ
sequence. The 83 aa APP fragment (C83) then suffers the action of the γ-secretase, liberating the p3 peptide and the
AICD fragment. The amyloidogenic pathway involves the sequential cleavage of APP by the β-secretase which releas‐
es the soluble ectodomain sAPPβ. The remaining C99 fragment of APP is then cleaved by the γ-secretase, resulting in
the formation of the Aβ peptide. Due to its high propensity to aggregate, Aβ peptide oligomerizes, accumulates and
forms amyloid senile plaques, in turn leading to the described alterations of AD. Current therapeutic approaches in
AD include: (1) inhibition of β- and γ-secretases, (2) improving Aβ clearance, and (3) amelioration of inflammation and
synaptic dysregulation.
Although tightly related to AD onset, APP processing is a normal metabolic event and Aβ is
a normal product of cellular metabolism throughout life, circulating as a soluble peptide in
biological fluids [53]. Plus, Aβ deposition can also be found, together with NFTs, in the brain
of non-demented elderly people [54].
2.4. Alzheimer’s disease hypotheses
AD is one of the human diseases with the highest number of hypothesis formulated trying to
explain its pathogenesis, with very different and plausible molecular mechanism to back them
up. Within the list, the amyloid cascade hypothesis stands out, together with the so-called “tau
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and tangle” hypothesis, strengthened by the fact that they are based in the two hallmarks of
AD.
2.4.1. Amyloid cascade hypothesis
Since its formalization, in 1992 by Hardy and Higgins, the amyloid cascade hypothesis has
had a prominent role in explaining the etiology and pathogenesis of AD. They suggested that
amyloid deposition was the primary influence driving AD pathogenesis [55], due to two key
observations: the detection of Aβ as the main constituent of amyloid plaques, and the discovery
of mutations in the APP, PSEN1 and PSEN2 genes associated with FAD [56]. This hypothesis
stated that a dysregulation in APP processing or Aβ clearance would provoke an increase in
the Aβ42/Aβ40 ratio, which would promote aggregation, accumulation, and plaque formation.
In turn, this would be responsible for the subsequent pathology (including tau aggregation,
phosphorylation, neuronal attrition, and clinical dementia) [57]. Due to its inability to entirely
explain AD pathogenesis, especially by the lack of correlation between plaque burden and
clinical manifestations [58], this hypothesis has been upgraded over the past few years.
Scientists started to divert their attention from the effects of the amyloid deposits, to study the
other forms (monomers, oligomers, and protofibrils—usually shorter and thinner then mature
fibrils) [59] of Aβ peptide-induced neurotoxicity. Some studies suggest that Aβ toxicity
functions in a plaque-independent manner, indicating that oligomeric intermediates present
higher toxicity to the cells [60] and that activation of signaling pathways due to intraneuronal
accumulation of Aβ oligomers is responsible for tau hyperphosphorylation and subsequent
deposition [61]. Several explanations have been proposed, with some defending that oligo‐
meric toxicity is related to a greater capacity for diffusion and a larger collective surface area
for interacting with neuronal and glial cells [60], while other proposed that it is not related to
a specific prefibrillar aggregate (dimer, trimer, and so on) but rather to the propensity that each
species has to grow and undergo fibril formation [62].
A more consensual vision about Aβ is that it possesses a dual role: On one hand, it can be a
neurotrophic agent or a neuroprotector against excitotoxicity (by activating the phosphatidy‐
linositol-3-kinase (PI-3K) pathway); on the other hand, an inducer of neuronal degeneration
(at high concentrations) in mature neurons [63].
Other interesting and amyloid cascade-opposite hypotheses have been proposed, stating that
Aβ should not be seen as the initiating factor for neurodegeneration in AD, but instead, its
deposition is nothing more than a protective mechanism to neuronal insult, in which Aβ binds
and removes harmful substances by blocking them in plaques [64, 65].
2.4.2. Tau hypothesis
“Tauists” defend a collection of ideas that maintain the primacy of NFTs formation as the AD-
causing event, which Mudher and Lovestone designated as the “tau and tangle hypothesis”
[57]. It started to emerge due to solid evidence that amyloid plaques do not account for the
complex pathophysiology of AD [66], opposed to the observed highly positive correlation
between NFTs and cognitive deficits [67]. It argues that in AD the normal role of tau (micro‐
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tubules stabilization) is impaired and that NFTs accumulate and occupy much of the neuron,
resulting in neuronal death. This was supported by the visualization of the extracellular tangles
in the shape of neurons, abundant in the late stages of disease [57]. Also, the discovery of
mutations within the tau gene that cause fronto-temporal dementia and parkinsonism linked
to chromosome 17 (FTDP-17), demonstrating that tau dysfunction, in the absence of amyloid
pathology, was enough to cause neuronal loss and clinical dementia [68], further strengthened
this hypothesis. However, tau mutations do not originate amyloid plaques, whereas APP and
presenilin gene mutations give rise to amyloid and tau depositions, strongly evidencing that
amyloid pathology is upstream of tau pathology [57]. More recently, a more embracing tau
hypothesis was proposed, in which a series of damage signals (Aβ oligomers, oxygen-free
radicals, iron overload, cholesterol levels in neuronal rafts, low-density lipoprotein (LDL)
species and homocysteine, among other) trigger, by innate immunity, the activation of
microglial cells with the consequent release of pro-inflammatory cytokines that modify
neuronal behavior through anomalous signaling cascades, which finally, promote tau hyper‐
phosphorylation [66]. In turn, tau hyperphosphorylation will contribute to further activation
of microglial cells and stimulation of the deleterious cycle, which will lead to progressive
neuronal degeneration [66]. The degree of tau phosphorylation in the AD brain is reasonably
well correlated with the severity of AD symptoms; however, fetal tau, a much more phos‐
phorylated form of tau than adult tau, does not induce AD-like pathology [69]. In summary,
there is no direct evidence for the neurotoxicity of hyperphosphorylated tau (as in the case of
Aβ toxicity).
2.4.3. “Other” hypothesis
2.4.3.1. GSK-3 hypothesis
Glycogen synthase kinase-3 (GSK-3), a multi-tasking kinase with major roles in brain signaling,
has been recently proposed as a central player in AD pathology. This was supported by
observing that the deregulation of this protein is responsible for many of the pathological
hallmarks of the disease, in both sporadic and familial AD cases [70]. It was suggested that the
hyperactivity of GSK-3β, the most abundant of two isoforms (GSK-3α and GSK-3β) expressed
in neurons, is intimately involved with cognitive impairment [71], Aβ production [72], tau
hyperphosphorylation [73], acetylcholine synthesis [74], neuronal death [75], and neuroin‐
flammation [76] in AD. Furthermore, regarding Aβ interaction, it was observed that Aβ also
regulates GSK-3β activity [77, 78] making it difficult to establish which event is located
upstream. Thus, this hypothesis is seen as an integration and extension of the amyloid cascade
hypothesis, still conferring to Aβ a central role in AD pathology. Although GSK-3 modulation
appears to be an excellent therapeutic approach, no effective result has been observed in trials,
perhaps due to its activity in multiple targets.
2.4.3.2. Oxidative stress/mitochondrial hypothesis
The brain is especially vulnerable to free radical damage as a result of its high oxygen con‐
sumption rate, abundant fatty acids content, and the relative low levels of antioxidant enzymes
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[79]. The most appealing feature of the oxidative stress hypothesis is its slow and cumulative
damaging nature that could, over time, account for the late life onset and slowly progressive
nature of AD, and neurodegeneration in general [80]. Also supporting this hypothesis is the
suggested unbalanced levels of heavy metals in the brain, among others, iron (Fe), copper (Cu),
aluminum, and mercury, which function as catalysts for oxygen free radical generation [80].
There has been high controversy in the measurement of these elements, especially Fe, but most
studies reveal an apparent unbalance in AD brains compared to controls. In a recent study, Fe
was found significantly increased in patients with severe AD [81] (as previously reported [82]).
Nonetheless, some consider that this “accepted” elevation, even if significant in some studies
of AD pathology, does not account for brain degeneration, and so, presents itself as a mis‐
leading therapeutic target with considerable risks for patients (reviewed in [83]). As for Cu, it
has been shown to be decreased in AD brains [81], which at first goes against the oxidation
hypothesis. More recently, and also in the presence of some contradictory results [84], copper
was found to bind strongly to Aβ aggregates, inhibiting in vitro amyloid fibril formation [85].
In addition, and when bound to the aggregates, copper exhibited a redox role, by degrading
hydrogen peroxide [86]. Protein and DNA oxidation (in particular mitochondrial DNA), and
lipid peroxidation (which affects the phospholipid-rich membrane) were also found to be
increased in AD brains [80].
Another hypothesis intimately related to the brain redox status is the mitochondrial cascade
hypothesis [87]. Mitochondria are considered the cell “powerhouses”; however, when in a
non-physiological energy production, they can provoke severe damage by increasing the
reactive oxygen species (ROS). Curiously, mitochondria are the first target of ROS, suffering
DNA oxidation, which may lead to a further increase of ROS production, generating a vicious
cycle [88]. The authors of this hypothesis state that sporadic and autosomal dominant AD are
not etiologically homogeneous and that mitochondrial dysfunction works as a link for both.
Very briefly, in autosomal dominant forms, Aβ-induced mitochondrial dysfunction leads to
the other AD-characteristic histopathologies, while in sporadic AD, mitochondrial malfunc‐
tion induces the AD pathologies, including processing of APP to Aβ [89].
2.4.3.3. The cholinergic hypothesis
The cholinergic hypothesis was proposed after the observation of a decrease of choline
acetyltransferase (ChAT) in AD patients [90]. It states that the loss of cholinergic cells in the
septal nuclei and basal forebrain (described in patients with advanced AD [91]) compromises
the innervation of the cerebral cortex and related structures, which play an important role in
cognitive functions, especially memory [92]. More recent studies have suggested a bidirec‐
tional pathway linking Aβ toxicity in cholinergic dysfunction and the interaction of cholinergic
regulatory mechanisms in the processing of APP [93]. Discrediting this hypothesis, later
studies showed that the cholinergic degeneration [94] and the decrease in ChAT enzyme
activity [95] are not observable in the early stages of disease. This was accompanied by the fact
that treatment with acetylcholinesterase inhibitors does not offer long term cure, although it
has shown consistent, despite modest, benefits in symptoms improvement [96]. Nonetheless,
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some studies point out that compensatory mechanisms could overcome the cholinergic defects,
disguising its effects in early stages of AD or mild cognitive impairment [97].
2.4.3.4. Calcium hypothesis
The calcium hypothesis was first introduced by Khachaturian in 1982, stating that cellular
mechanisms which maintain the homeostasis of cytosolic Ca2+ play a key role in brain aging
and that sustained changes in Ca2+ homeostasis could provide the final common pathway for
age-associated brain changes [98], or in this case, be the proximal cause of neurodegeneration
in AD. Out of curiosity, this proposal was purely speculative at the time, only sustained on
circumstantial evidence from a handful of studies [98]. It was observed that the persistent
elevation of the levels of Ca2+ leads to the constant elimination of newly acquired memories,
due to a stimulation of long-term depression mechanisms [99]. In fact, calcium signaling
dysfunctions occur during the initial phases of the disease, and even before the development
of pronounced symptoms [100]. However, whether it is calcium dyshomeostasis that provokes
Aβ production and accumulation [101], or vice-versa [102], remains to be elucidated. Either
way, in addition to the Aβ unbalance, increased levels of Ca2+ promoted protein tau hyper‐
phosphorylation [103]. It was also suggested that amyloid oligomers induce membrane
permeabilization, leading to increased intracellular Ca2+ concentration [104]. Nevertheless,
there is some disagreement as to the mechanism by which amyloid oligomers increase
intracellular calcium.
2.5. Biomarkers and risk factor
Despite of the extensive Knowledge on the causative gene mutations responsible for familial
AD, the sporadic (non-genetic) form of this disease, which results from the diverse interactions
between genetic and environmental factors, is still lacking characterization. Thus, researchers
are continuously looking for specific molecules that should be altered exclusively in AD, and
preferentially in the asymptomatic period. This, combined with the meticulous description of
the patient risk factors, may give the opportunity for an early action and increase the success
rate of therapeutics.
2.5.1. Biomarkers
By definition, and according to the International Programme on Chemical Safety, biomarker
is “any substance, structure, or process that can be measured in the body or its products and
influence or predict the incidence of outcome or disease” [105]. The search for early AD
biomarkers has been highly targeted over the last years, as investigators believe that the
generation of an effective treatment for AD is only possible if the disease is detected at very
early stages. Thus, the discovery of biomarkers is of extreme importance for the early diagnosis
of AD and even for predicting the conversion of MCI into AD patients.
The search for solid AD biomarkers started with those who seem to be altered in this condi‐
tion when compared to normality. Several studies showed that the combination of CSF to‐
tal- and phospho-tau, and CSF and plasma Aβ42 is able to predict with increased sensitivity
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and specificity the development of AD in patients with MCI [21, 106, 107], in addition to the
already established role of the ApoE-ε4 isoform [108] (major susceptibility gene—see Sec‐
tion 2.5.2. Risk Factors). Studies in FAD-causing mutations carriers showed increased levels
of CSF total-tau and plasma Aβ42, although having reduced CSF Aβ42 levels, at least
10 years before the symptoms establishment [106]. Also, the ratio of Aβ42/Aβ40 in CSF and
plasma was found decreased, respectively, for non-demented mutation carriers [109] and
cognitively normal elders (which evolved to MCI or AD) [110]. Other CSF biomarkers, such
as BACE-1 [111] and sAPPα/β [112], are also suggested; however, independent studies were
not consistent [106], possibly due to technical difficulties in the biomarkers quantification
[113]. Our group has also proposed TTR as a biomarker in plasma, demonstrating a nega‐
tive correlation with AD severity [114], which supported prior observations for CSF levels.
In that study, the authors also considered TTR a selective biomarker for AD [115]. Other
studies contradict this idea suggesting that TTR potential as biomarker raises some doubt
since its levels appear to fluctuate substantially within a single individual over a 2-week
interval [116].
In addition to the so-called fluid biomarkers, physicians have at their disposal powerful
imaging technology. With the improvement in PET (positron emission tomography) and MRI
(magnetic resonance imaging) spectroscopy resolution, neuroimaging has been gaining
importance and increasing the confidence in AD diagnosis. Due to the possibility of using
specific tracers, such as a derivate of thioflavin T that crosses the blood–brain barrier (BBB)
and binds selectively to Aβ (C11-labeled Pittsburgh Compound B–PiB), it is possible to identify
amyloid deposition in the brain in vivo [117]. In 2004, Klunk and colleagues performed the
first study of brain amyloid imaging (BAI) using the PiB compound, in which they showed a
robust relationship between amyloid deposition and PiB retention [118]. The combination of
increased BAI signal, low CSF Aβ42, and high CSF p-tau in a subject with dementia is seen as
a “definite” diagnosis of AD. Furthermore, BAI and CSF profiles can be used to predict patients
with MCI who will progress to frank dementia with high degree of confidence [119]. Despite
the value of this compound, the resulting data should be subjected to careful analysis since
healthy subjects also present amyloid deposition, hindering the differentiation between
symptomatic AD and asymptomatic controls with amyloid plaques [120]. MRI (structural
evidence) is also a common technique often used, alone or in combination with CSF tau and
Aβ42, to predict development of AD [121]. Curiously, a recent study showed that the MRI
together with PiB-PET makes the best combination of biomarkers, thus showing the best AD
predictive value [119].
2.5.2. Risk factors
2.5.2.1. Environmental factors
As Stephen King wrote in The Gunslinger: “Time's the thief of memory,” and so, the most
worldwide accepted (and intuitive) risk factor is aging. In every species, age brings a slowing
of brain function [122], thus preventing the brain to properly respond/recover from insults.
The increasing of life expectancy, in addition to the increasing of population (attributed to the
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postwar “baby boom”), turned aging in a major risk factor. Also gender appears to play a role
in disease development, since data show that women are more prone to this disease than men.
Although women present higher life expectancy, also in younger study groups (60–80 years),
where differences in death rate are insignificant, women present higher incidence of cases
[123]. The specific mechanism is unknown; however, several factors have been proposed to
influence, such as: age-related sex hormone reduction, risks of other diseases (diabetes,
depression, cardiovascular disease), and differences in brain anatomy and metabolism [124].
The cardiovascular risk factors, which appear sometimes as a distinct group of factors, include
diabetes mellitus [125], overweight [126], hypertension [127], and high cholesterol levels [128].
Individually or in cooperation, these factors increase the predisposition for cognitive decline.
The midlife control of the above cardiovascular factors has been associated with a reduction
in white matter lesions in late life [127]. As for cholesterol, results appear to be inconsistent;
however, lipid-lowering treatments present benefits against white matter lesions [126].
Contrasting with the previous risk factors, wine consumption, coffee consumption, the use of
non-steroidal anti-inflammatory drugs (NSAIDs), and physical activity are associated with
reduced risks, thus showing some protective effects [129].
2.5.2.2. Genetic factors
ApoE exists as three isoforms ε2, ε3 and ε4, with ε3 having the highest prevalence. As Corder
and colleagues stated, in 1993, ApoE plays an important role in AD, with the risk of developing
disease increased in carriers of the ApoE-ε4 allele, such that a double dose of this allele was
nearly enough to cause AD by the age of 80 [130]. Despite the broad molecular evidence about
ApoE role in AD, its genetic variation is also present in other kinds of neurological disorders,
including Parkinson’s disease and multiple sclerosis [22]. In 2009, three novel AD genes were
identified, presenting high degree of association: CLU (clusterin or apolipoprotein J), CR1
(complement component (3b/4b) receptor 1), and PICALM (phosphatidylinositol-binding
clathrin assembly protein). Down’s syndrome (or trisomy 21) is also considered a genetic risk
factor. This condition is the result of a third copy of the chromosome 21, which coincides with
the location of the APP gene [131], giving rise to an increased accumulation of Aβ.
2.6. Drugs and treatments
Due to the complexity of AD, a vast number of targets and pathways may be chosen to
intervene. Cholinergic degradation inhibitors, immunotherapy, secretase inhibitors, anti-
inflammatory drugs, and tau- and Aβ-deposition interfering drugs (Figure 1) are but a few
examples of the many classes of drugs that are being tested at the moment.
The first drugs developed for AD, acetylcholinesterase inhibitors (AchEI), aimed at increasing
acetylcholine levels (see “Cholinergic hypothesis”). Currently, FDA has five drugs approved
for the “treatment” of AD in the initial stages: 4 AchEI (Donepezil, Rivastigmine, Galantamine,
and Tacrine) and 1 NMDA receptor antagonist (Memantine) (http://www.alzforum.org). As
referred above, they treat and ameliorate the symptoms, but do not cure.
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In 2010, Rinne and colleagues showed for the first time target engagement from a disease-
modifying drug in humans, using the monoclonal anti-Aβ antibody bapineuzumab [132,
133]. This study showed a reduction of fibrillar amyloid in the brain of AD individuals, but
did not improve cognition and stopped at phase 3 [133]. Crenezumab, another anti-Aβ, was
selected for pre-symptomatic treatment trials of Colombian mutant PSEN1 kindred [133],
however, showed extensive cross-reaction with non-Aβ related proteins [134]. Intravenous
immunoglobulins (IVIG) have also been proposed as a potential treatment, based on the
hypothesis That IVIG contain naturally occurring antibodies that specifically promote
clearance of Aβ peptides from the brain [135].
β- and γ-secretase modulators [133], Aβ and tau deposition modulators (e.g., scylloinositol
and methylene blue, respectively [39]), and molecules addressing oxidative damage (resver‐
atrol) are also potential drugs under study. Recently, deep brain stimulation (DBS) performed
by the group of Dr Lozano in AD patients showed promising results, with improvements and/
or slowing in the rate of cognitive decline [136], increased hippocampus volume and glucose
metabolism [137]. The authors propose that DBS is able to influence the structure of the brain
and that hippocampal atrophy can potentially be slowed, suggesting restorative properties to
DBS [137].
A general recommended therapy is a good diet and a healthy lifestyle, in order to control
cardiovascular risk factors, decreasing cerebrovascular events. No effective treatment has been
found, thus increasing the interest for the early diagnose of AD, to allow a more effective and
early stage intervention.
3. Blood–brain barrier and Alzheimer’s disease
The BBB is a profoundly specialized brain endothelial structure of the differentiated neuro‐
vascular system. These specialized endothelial cells interacting with astrocytes, microglia, and
pericytes, confine components of the circulating blood from neurons. Furthermore, the BBB
controls the chemical composition of the neuronal environment which is required for the
functioning of neuronal circuits, synaptic transmission, synaptic remodeling, angiogenesis,
and neurogenesis. BBB malfunction, through the disruption of the tight junctions (TJs) and
alteration of the transport of molecules between blood and brain, brain hypoperfusion, and
inflammatory responses, may begin or contribute to the process of different diseases such as
AD, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis. These data support
developments of new therapeutic strategies for the neurodegenerative disorders focused at
the BBB [138].
3.1. The blood–brain barrier: the earliest findings
In 1885, when scientist Paul Ehrlich injected trypan blue dye into the bloodstream of mice, he
noted that the stain colored all of the animal organs, except the brain [139]. In 1913, one of the
Ehrlich's students, Edwin Goldmann, performed a follow-up experiment by injecting the same
dye into the brain of mice. He observed that injection of trypan blue directly into the CSF
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stained all cell types in the brain but failed to penetrate into the periphery [140]. Although
aiming at finding new compounds that could attack disease-causing microbes, these experi‐
ments suggested a physical barrier between the brain and the blood, becoming the stepping
stones on BBB research. Lewandowsky was the first to use the term blood–brain barrier while
studying the limited permeation of potassium ferrocyanate into the brain [141]. However, it
took until the 1960s for the specific anatomy of the network of brain–blood vessels comprising
the BBB to be glimpsed [142]. Using electron microscopy, in 1967, Reese and Karnovsky
showed that the BBB is localized at the level of TJs between adjacent brain endothelial cells
[143, 144].
It is now known that the brain of mammals is separated from the blood by the BBB, localized
to the brain capillaries and pia-subarachnoid membranes, and by the blood-CSF barrier,
confined to the choroid plexus [145]. At the junctional complex formed by the TJs and adherens
junctions (AJs), brain endothelial cells are connected to each other [142]. Transcellular transport
at the BBB occurs through several mechanisms including passive and active transport through
different receptors and transporters. Interestingly, endothelial cells, pericytes, and astrocytes
present at the BBB also express several enzymes such as cholinesterase, aminopeptidases and
endopeptidases that alter endogenous and exogenous molecules, which can negatively
influence neuronal function. This produces a metabolic barrier which protects the central
nervous system (CNS) [146].
3.2. The neurovascular unit at the BBB; endothelial cells, pericytes, and glial cells
3.2.1. Endothelial cells and pericytes
A cerebral capillary lumen is enclosed by a single endothelial cell. Anatomically, the BBB
endothelial cells are distinguished from those at the periphery by enhanced mitochondrial
content [147], loss of fenestrations [148], least pinocytotic activity [149], and the presence of
TJs [150]. The BBB tightly sealed monolayer of endothelial cells usually prevents the free
exchange of solutes between blood and brain [151] except for the lipid-soluble molecules
smaller than 400 Da with less than nine hydrogen bonds, which can cross the BBB without any
support, via lipid-mediated diffusion [146].
As for pericytes (granular or filamentous), they are connected to the abluminal membrane of
the endothelial cells [152]. Pericytes and endothelial cells are ensheathed by the basal lamina,
composed of collagen type IV and other extracellular matrix proteins [153]. However, there is
not much known about the involvement of pericytes at the BBB, but the addition of pericytes
to co-cultures of endothelial cells and astrocytes has been shown to stabilize capillary-like
structures [154]. In conditions associated with increased BBB permeability such as hypoxia or
traumatic brain injury, pericytes have also been shown to migrate away from brain microves‐
sels [155, 156]. Moreover, pericyte-derived angiopoietin provokes expression of TJs such as
occludin in endothelial cells [157], confirming that pericytes are involved in the maintenance
of the barrier properties in the cerebral endothelium [142].
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3.2.2. Glial cells
Astrocytes are another cell type present in the neurovascular unit. These cells are usually
located between neurons, pericytes, and capillary endothelium, and communicate with these
cells via their several foot processes [138]. It is long believed that astrocytes are crucial in the
development of the BBB properties [158]. It has been shown that co-culture of brain endothelial
cells with astrocytes can enhance TJs of the brain endothelium [159]. Furthermore, endothelial
cultures incubated with astrocyte-conditioned media have shown to improve BBB character‐
istics in vitro by de novo protein synthesis of γGTP in cerebral microvessel endothelial cells,
which indicate that the glial cells may induce the cerebral capillary endothelial cells to express
differentiated properties which allow the endothelium to function as the blood–brain barrier
[160]. Also, astrocytes have been shown to regulate cerebral microvascular permeability [161],
via dynamic calcium signaling between astrocytes and the endothelium [162]. This has been
explained by Zonta et al., whereby an increase in neuron-induced astrocyte calcium promotes
secretion of vasodilatory substances from perivascular astrocyte endfeet, resulting in im‐
proved local blood flow [163]. This work constituted a breakthrough in the knowledge of both
astrocyte function and regulation of the activity-dependent cerebral blood flow [164].
Finally, another glial cell type present in the BBB is microglia which migrates from the yolk
sac into the CNS parenchyma during embryogenesis [165]. Microglia performs critical
functions in innate and adaptive brain immune responses. Microglia, when activated, trans‐
forms from “ramified” to an "ameboid" and ultimately to a “phagocytic” form. This evolution
is correlated with alterations in expression of surface antigens and cytokines release [138].
Studies have shown that perivascular microglial cells are derived from bone marrow [166].
In vivo studies demonstrated that resident microglia cells in the brain parenchyma also
communicate with CNS microvessels. This may suggest that microglia plays an important role
in regulating BBB features during embryogenesis and diseases [167], besides an indisputable
function in CNS development and homeostasis [168]. Furthermore, it has been shown that
during embryonic stages of CNS vascularization, stabilization, and fusion of brain endothelial
cells are mediated by resident microglial cells [167]. Also, interestingly, it has been shown that
specific depletion of microglia results in reduced vessel density in a mouse model of choroidal
neo-vascularization [169]. There are studies which suggest that microglial activation may be
related to BBB disruption [170] apparently by producing ROS, through NADPH oxidase,
which in turn impairs BBB function. Furthermore, TNF-α released from activated microglia
has shown to affect BBB integrity, as permeability of endothelial cells co-cultured with
microglia, was increased when microglial cells were activated by LPS and it was blocked by a
neutralizing antibody against TNF-α, indicating that TNF-α contributes to BBB dysfunction
[171]. The post-traumatic inflammatory response is shown to be associated with expression of
cytokines such as IL-1β or metalloproteinases particularly MMP2, 3 and 5 produced mainly
by microglia at the lesion site. It has also been demonstrated that these proteins can cause
disruption of the basal lamina and/or redistribution and degradation of the TJs complexes
[172, 173] resulting in BBB breakdown and neurological disorders after traumatic injury [174].
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3.3. Junctional complexes and cytoskeleton linked proteins at the BBB
The presence of junctional complexes is one of the main characteristics of inter-endothelial
space of the cerebral microvasculature which include TJs, AJs, and possibly gap junctions. Both
TJs and AJs restrict permeability across the endothelium, whereas gap junctions (if present)
mediate intercellular communication [175].
3.3.1. Tight junction proteins
Occludin, the first integral membrane protein within the TJ family identified [176], is a 60–
65 kDa protein with four transmembrane domains which is highly expressed in the cerebral
endothelium [177, 178], whereas it is much less present in non-neural endothelial cells [179].
A construct with a deletion in the N-terminal of occludin showed a considerable effect on the
TJ integrity [180]. Deletion of occludin in mice has been shown to cause a complex phenotype
and postnatal growth retardation [181]. However, occludin functions are not limited to its role
as a TJ protein. For instance, there are studies demonstrating that occludin can regulate
epithelial cell differentiation [182] and control cell apoptosis in mouse hepatocytes [183]. Also,
it has been shown, in a mouse model of multiple sclerosis, that occludin dephosphorylation
leads to noticeable signs of disease which occur just prior to apparent changes in the BBB
permeability [184]. In cerebral ischemia, occludin and other TJs were shown to be vulnerable
to attack by matrix metalloproteinases [185].
The claudin family, 20–24 kDa proteins, includes more than 20 members that build TJ strands
through homophilic interactions [186]. Claudin 3, 5, and 12 play important roles at the BBB
[187, 188]. Each claudin regulates the diffusion of a group of molecules of a certain size. For
instance, mice neonates with deletion of claudin-5 die due to a size-selective loosening of the
BBB for molecules smaller than 800 Da [188]. It is speculated that claudins determine the
primary “seal” of the TJ and occludin functions as an additional support structure [142]. It has
been demonstrated that overexpression of claudin species can induce development of TJ-like
strands, while expression of occludin does not lead to the formation of TJ; rather, occludin only
localizes to TJ in cells that have already been transfected with claudins [189].
In addition to the claudin/occluding proteins, junctional adhesion molecules (JAMs) perform
an important role in the organization of TJ assembly as it has been reported that these proteins
can reduce cell permeability and enhance resistance to macromolecules [190]. JAM-1, a 40-kDa
member of the IgG superfamily composed of a single membrane-spanning chain with a large
extracellular domain [191], is postulated to mediate the attachment of neighboring cell
membranes via homophilic interactions [192]. However, there is not much known about JAMs
exact function in the mature BBB, but in the rat cortical cold injury model, a characterized in
vivo model of BBB breakdown it has been shown that endothelial JAM-1 is significantly
reduced which strengthens the idea that JAM-1 contributes to TJs integrity [193].
3.3.2. Adherens junction proteins
The first component of AJs is the vascular endothelial (VE)-cadherin, an endothelial-specific
integral membrane protein which is linked to the cytoskeleton via catenins [175] and mediates
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cell-cell adhesion via homophilic interactions between the extracellular domains of proteins
expressed in adjacent cells [194]. In vitro and in vivo studies have shown that VE-cadherin is
required for the cells to regulate vessel maintenance, that is, for the correct organization of the
new vessels and for the endothelial integrity in the quiescent vessels [195]. Various mecha‐
nisms have been suggested for how VE-cadherin regulates endothelial functions; such as direct
activation of signaling molecules with a role in survival and organization of the actin cytos‐
keleton and regulation of gene transcription cofactors and formation of complexes with growth
factor receptors [138].
Even though AJs are required at the BBB to decrease the endothelial permeability [196], it is
principally the TJs that present the low paracellular permeability and high electrical resistance
[142, 197].
Another component of AJs is Platelet endothelial cell adhesion molecule 1 (PECAM-1), an
integral membrane protein of the Ig superfamily with six extracellular domains, a short
transmembrane, and a large cytoplasmic domain which is highly expressed in blood and
vascular cells especially endothelial cells [198]. PECAM-1 plays a major role in the migration
of leukocytes across endothelium [138] and contributes to the steady-state barrier function of
endothelial cells. It also functions as a mechano-sensor and stimulates reconstruction of the
barrier integrity following perturbations, including the BBB [199, 200]; all physiologic proc‐
esses that rely on the junctional integrity and signaling [198].
3.3.3. Associated proteins
There are various proteins in the cytoplasm that associate with the transmembrane compo‐
nents of the TJ [142]. Multi-domain scaffolding proteins of membrane-associated guanylate
kinase-like homolog family, including zonulae occludentes (ZO) proteins, such as ZO-1 and
ZO-2, are characterized for their contributing to the cytoskeletal anchorage for the transmem‐
brane TJ proteins, binding to the claudins, occludin, and actin [201, 202] and controlling the
correct distribution of claudins [203].
ZO-1, a 220-kDa protein, is one of the first and best-studied proteins in TJs [204]. It is expressed
in epithelial and endothelial cells and even other cells which do not have TJs [205]. It has also
been observed to be associated with AJs [206] and gap junction proteins [207]. ZO-1 is located
just below the TJ membrane contact points and has been found to be important for both
function and stability of TJs. ZO-1 dissociation from the junctional complex is shown to be
correlated with increased permeability in the BBB in vitro model [208]. ZO-2, a 160-kDa protein
with a high sequence homology to ZO-1 [209], interestingly, has been demonstrated to function
redundantly with ZO-1, replacing it and promoting the formation of TJ in the cells lacking
ZO-1 [210].
Another component present in the junctional complexes is actin. Although actin has been
basically considered structural in function, it is now obvious that the anchorage of AJs and TJs
to the actin cytoskeleton is critical for both barrier stability and also for the regulation of cell
polarity, cellular movement, fluid sensing, and cell-contact inhibition [211]. Studies using mice
lacking the actin-binding protein dystrophin have demonstrated increased brain vascular
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permeability due to disorganized α-actin cytoskeleton in endothelial cells and astrocytes [212].
These findings demonstrate that properly arranged actin filaments and their binding to the TJ
and/or AJ proteins are critical for normal barrier function. Studies have also shown that HIV-1
gp120 and alcohol are able to alter the cytoskeleton and induce stress fiber actin formation,
causing increased permeability of the human BBB endothelium [213]. It has been suggested
that alcohol-mediated changes in the brain endothelial cells (BEC) monolayers may increase
diffusion of plasma components and viral penetration across the BBB, and therefore, especially
at levels attained in heavy drinkers, accelerate HIV-1 penetration into the brain [138].
3.4. Transport at the BBB
Transcellular transport at the BBB happens through several mechanisms. Small lipophilic
molecules can access the brain by passive diffusion. Brain CSF bulk flow mediates transport
of molecules with different sizes into the CSF at a slow rate [214]. For potentially toxic
molecules and metabolic waste products, the CSF works as a sink. These molecules are then
eliminated from the CSF back into the blood by active transport or facilitated diffusion across
the choroid plexus epithelium, or by vacuolar transport across the epithelial arachnoid
granulations [138]. Efflux pumps return many undesired molecules back to the blood to
regulate passive transport into the brain [215]. The flow of the plasma oxygen and carbon
dioxide across the BBB is diffusive. Therefore, oxygen supply and carbon dioxide elimination
are blood-flow dependent, so the gas transport is sufficient as long as cerebral blood flow is
within physiological limits [216].
Small polar molecules, such as glucose, amino acids and nucleosides, can pass the BBB by
carrier-mediated transport. These carriers can be multi-ligands or specific to only one mole‐
cule, such as GLUT1 glucose transporter, the L1 large neutral amino acid transporter, and the
CNT2 adenosine transporter which have been cloned from BBB-specific cDNA libraries [146].
The direction of the concentration gradient is usually from blood to brain, regulated by brain
demands and the concentration of metabolites in plasma [138]. Ion transporters such as the
sodium pump localized on the abluminal membrane are important to sustain the high-
concentration gradient for sodium at the BBB, so that sodium-dependent transport can happen.
Also, sodium–hydrogen exchanger expressed at the luminal membrane and chloride–
bicarbonate exchanger expressed at both sides [217] play significant roles in regulating
intracellular pH in the endothelium.
Moreover, large solutes, such as proteins and peptides, are transported across the BBB by
receptor-mediated or adsorption-mediated endocytic transport [218, 219]. Analysis of the rat
BBB transcriptome has shown that 10–15% of all proteins in the neurovascular unit are
transporters which emphasize the critical role of these molecules at the BBB [215, 220]. As a
consequence of this controlled transport, the concentration of amino acids and proteins can
suffer considerable variations, whereas relatively small differences exist in the concentration
of ions between blood and CSF [221].
In the BBB, the ABC transporters for efflux are permeability glycoprotein (P-gp, multidrug
resistance protein, ABCB1), the multidrug resistance-associated proteins and breast cancer
resistance protein [222, 223] whose major role is to operate as active efflux pumps, transporting
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a diverse range of lipid-soluble compounds out of the brain capillary endothelium and the
CNS, eliminating potentially neurotoxic endogenous or xenobiotic molecules [216, 224]. P-gp
is expressed at the luminal and abluminal membrane, as well as in pericytes and astrocytes
[225], and is distributed along the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi
complex, and rough ER [138]. The endothelial cells at the BBB also express several transporters
for hormones, some cytokines, and chemokines [226]. Large proteins, such as transferrin, LDL,
leptin, immunoglobulin G (IgG), insulin, and insulin-like growth factor also use receptor-
mediated transport systems to pass through the BBB [146].
Internalization of ligands and receptors from the plasma membrane is cholesterol sensitive
[227] and comprises endocytosis of caveolae, vesicles enriched in caveolin-1 [228]. The caveolar
membranes carry several receptors including those for insulin, albumin, receptor for advance
glycation endproducts (RAGE), LDL, HDL [229] and are also closely associated with P-gp.
Moreover, caveolin-1 can affect the levels of TJs in endothelial cells of the BBB [230]. Interest‐
ingly, study of the ultrastructure of the BBB in young and aged mice during ischemia has
demonstrated that permeability is associated with a remarkable increase in endothelial
caveolae and vacuoles although TJs were generally intact [231].
3.5. Aβ clearance at the BBB
Increase in either total Aβ levels or the relative concentration of both Aβ40 and Aβ42 (where
the former is more concentrated in cerebrovascular plaques and the latter in neuritic plaques)
have been implicated in the pathogenesis of both familial and sporadic AD.
There are several identified pathways for the removal of the Aβ from the brain. Aβ peptides
mainly produced in neurons are degraded by peptidases. Through efflux transporters located
in cerebral vessels, Aβ flows out from brain parenchyma into the plasma. Aβ is also removed
through perivascular pathways into the cervical lymph nodes as Aβ within ISF diffuses in the
extracellular spaces of the brain parenchyma entering basement membranes of capillaries,
passing into the tunica media of arteries, and draining out of the brain. Aβ can also be taken
up by different cells in the brain [232]. A few AD cases are familial AD, associated with genetic
mutations which promote an increase in the production of Aβ [233]. On the other hand, the
cause of the sporadic AD, the majority of the AD cases, is considered to be the impaired
clearance of Aβ from the brain [234, 235]. In this viewpoint, AD is associated with cerebro‐
vascular disorder, which drives the accumulation of Aβ at the blood vessels (cerebral amyloid
angiapothy, CAA) and in the brain parenchyma, extracellularly [138, 236], and intraneuronal
lesions—NTFs [237].
In the healthy brain, Aβ concentration is accurately regulated by its rate of production, its
enzymatic degradation [238], its rapid clearance across the BBB through LRP1 [239, 240], and
influx back into the brain by RAGE [241]. These receptors are multi-ligand cell surface receptors
that, in addition to Aβ, mediate the clearance of a large number of proteins. P-gp, belonging
to the superfamily of ATP-binding cassette (ABC) transporters, is also involved in effluxing
Aβ out of the brain. While LRP1 and P-gp appear to mediate the efflux of Aβ from the brain
to the periphery, RAGE has been strongly implicated in Aβ influx back into the CNS. With
increasing age and also in AD pathology, the expression of the Aβ efflux transporters is
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decreased and the Aβ influx transporter expression is increased at the BBB, adding to the
amyloid burden in the brain and its gradual neurotoxic oligomerization [242]. Thus, continu‐
ous Aβ elimination by transport across the BBB and/or metabolism is essential to prevent its
potentially neurotoxic accumulations in the brain [234]. Studies have demonstrated several
transport proteins such as α2-macroglobulin, TTR, apolipoprotein E (apoE), and apolipopro‐
tein J (apoJ), which bind to Aβ and control its clearance, metabolism, and aggregation [243]. It
has been shown that apoJ can increase the BBB clearance of Aβ42 [244], while apoE disrupts
the clearance of free Aβ across the mouse BBB, in an isoform-specific manner (apoE4>apoE3
or apoE2), by driving Aβ transport from LRP1 to VLDLR which internalizes Aβ-apoE complex
at a slower rate than LRP1 [245]. Another transport pathway is the bulk flow of the ISF into
the CSF through the perivascular Virchow-Robin arterial spaces, which is followed by drainage
into the plasma across the arachnoid villi [243].
3.5.1. Aβ transport by LRP1
LRP1, the major efflux transporter for Aβ across the BBB [239] and a member of the LDL
receptor family, acts as both a multifunctional scavenger and a signaling receptor. LRP1 is
synthesized as a precursor molecule (600 kDa) in the ER. Then in the Golgi network, a cleavage
generates an 85 kDa transmembrane beta-subunit (containing two intracellular NPxY motifs)
that remains non-covalently connected to the extracellular 515 kDa alpha-subunit (containing
4 ligand-binding domains for more than 30 ligands) [246].
Transcytosis of Aβ across the BBB starts with its binding to LRP1 at the abluminal side of the
cerebral endothelium [239, 240]. However, this has been controversial due to the studies that
failed to demonstrate a role for LRP-mediated transcytosis, but rather showed a role for LRP
receptors in endocytosis and degradation of Aβ [247]. Anyway, the significant function of LRP1
in AD is not only portrayed by LRP1-mediated endocytosis of Aβ but also by data showing
that the cytoplasmic domain of LRP1 has been involved in APP processing [248]. Cleavage of
the extracellular domain of LRP1 by beta-secretase (BACE1) releases soluble LRP1 (sLRP1) in
plasma [249]. Reduced expression of LRP1 has been described during aging in animal models
and in AD individuals [240, 249]. In astrocytes, LRP1 also mediates degradation of amyloid
deposits via apoE [250].
3.5.2. Aβ transport by RAGE
RAGE, a multiligand receptor in the immunoglobulin superfamily, which can bind to various
ligands including Aβ and advanced glycation end products (AGE proteins) [251], is the most
influential influx transporter for Aβ across the BBB [241]. Interestingly, and unlike many
receptors (including LRP1), RAGE expression is triggered by the accumulation of RAGE
ligands, meaning that the levels of RAGE expression are determined by the levels of its ligands.
In the healthy brain, RAGE is expressed at minimal levels at the BBB, except at the endothelium
of bigger microvessels of the brain. However, when RAGE ligands increase in the AD brain,
RAGE expression rises in the affected cerebral vessels, neurons or microglia [251]. This
mechanism worsens the cellular dysfunction due to RAGE-Aβ interactions. Circulating Aβ
can enter the brain by a special receptor-mediated transport mechanism that is dependent on
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RAGE expression on the luminal surface of brain vessels [252]. Following Aβ binding to RAGE
at the luminal membrane of the BBB, transcytosis of circulating Aβ across the BBB into the
brain parenchyma and its binding to neurons occurs. Moreover, activation of NF-kB in the
endothelial cell leads to proinflammatory cytokines secretion and cerebral blood flow sup‐
pression [241]. Aβ-RAGE interaction not only generates oxidative damage to RAGE-express‐
ing neurons, which results in neuronal degeneration, but also activates microglial cells,
indirectly leading to inflammation [251]. Therefore, repression of Aβ-RAGE interaction in the
BBB can inhibit Aβ influx, oxidant stress, and cytokine production. The inhibitors of Aβ/RAGE
interaction have been shown to improve the BBB function and the cerebral blood flow
responses to the brain activation, and to reduce neuroinflammation. Some RAGE/Aβ blockers
are currently being tested in AD patients [138]. While RAGE is involved in the influx of Aβ
into the brain, the soluble isoform of RAGE (sRAGE) has been detected in the plasma. It seems
that sRAGE competes with cell-surface RAGE for ligand binding, thus increasing the elimi‐
nation of circulating Aβ [145].
3.6. BBB dysfunction in AD
Failure in the BBB function is an outstanding event in the development and progression of
several CNS diseases including multiple sclerosis [253], ischemia [254], Parkinson's disease,
and AD [255]. While in some of the diseases increased BBB permeability is an outcome and
consequence of the pathology (such as ischemic stroke), in other cases, BBB failure may be a
causative event for the disease (such as multiple sclerosis). Furthermore, BBB dysfunction can
be mild with temporary opening of TJs, or it can be a chronic breakdown [256], with changes
in transporters and enzymes happening at the same time [216].
Although cerebrovascular abnormalities have been noted in AD, the starting point between
BBB failure and AD pathology is not clear yet [142, 257]. Nevertheless, BBB homeostasis is
altered in the initial stages of AD leading to the production of proinflammatory cytokines and
suppressors of the cerebral blood flow by endothelial cells; then, amyloid deposits are observed
in cerebral capillaries and vessels in the later stages of AD [258]. A large number of alterations
in the structure and function of the BBB were shown to occur in AD. For instance: decreased
LRP1 expression in human brain microvasculature [239], increased LRP1 oxidative damage
[259], impaired microvascular P-gp [260], increased expression of RAGE in the cerebral vessels,
neurons and microglia [251]. Moreover, it has been shown to occur: decreased glucose
consumption by the brain, thus predicting a decay in cognitive function [261], which has been
described by the reduction in the GLUT-1 transporters expression (protein levels) in AD
hippocampus microvessels [262] but not a decrease in GLUT-1 mRNA levels [263]. Other
alterations have been described, such as: decreased endothelial mitochondrial density,
increased endothelial vacuolization, accumulation of collagen and perlecans in the basement
capillary membrane [264], and increased pinocytotic vesicles [265].Also, it has been reported
a reduced number and smaller diameter of capillaries in CNS implying the diminished overall
surface for LRP1-mediated transcytosis of Aβ across the BBB, and also a decreased length of
brain capillaries [266] which lowers transport of energy substrates and nutrients across the
BBB, and reduces the clearance of neurotoxins from the brain [138]; Overexpression and
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accumulation of occludin in frontal cortex and basal ganglia of AD brains [267] have also been
described as well as lower expression of genes such as the homeobox gene MEOX2 (or GAX),
a regulator of vascular differentiation [268]. Finally, activated microglia [269] and astrocytes,
the resident brain immune cells present in neurovascular unit of the BBB, have been observed
surrounding Aβ plaques in AD brains, releasing inflammatory cytokines, such as IL-1 and
IL-6, TNF-α, and transforming growth factor-β [174].
4. Periphery and Alzheimer’s disease
4.1. Aβ levels at the periphery
Although studies in rodents have shown an increase in plasma Aβ levels, data in human AD
patients have been contradictory; while some demonstrate increased levels of circulating Aβ
[270], others report decreased [271] or unchanged [272] levels. Nevertheless, the significant
role of circulating Aβ in AD pathology cannot be neglected. Interestingly, Aβ is also produced
outside the brain in considerable amounts by the platelets, skeletal muscle, vascular walls,
kidney, heart, liver, and by other non-neural tissues [273–275]. These pools may also provide
a dynamic exchange of Aβ between the brain and periphery. However, Aβ peptides in the
periphery cannot form filamentous structures, probably due to the presence of multiple
circulating molecules that bind Aβ and thereby change its free-plasma levels [276].
4.1.1. Plasma proteins involved in peripheral sink and clearance of Aβ
Continuous removal of Aβ, not only from the brain but also from blood and from the entire
organism, is essential for preventing its accumulation in the brain. Aβ in the plasma is bound
to a number of proteins such as albumin [277], apoE and apoJ [278], TTR and a soluble form
of LRP1 (sLRP1). In healthy human plasma, sLRP1 is a major endogenous brain Aβ sinker that
sequesters 70–90% of plasma Aβ. sLRP1 has been demonstrated to bind the majority of
circulating Aβ preventing RAGE-dependent influx of Aβ back to the brain, while improving
its systemic clearance [279]. These data confirm the peripheral sink hypothesis, which imply
systemic clearance of Aβ via binding proteins in serum and preventing its uptake through
RAGE. Accordingly, this explains how some therapeutics, such as peripheral administration
of sLRP1 or antibodies against Aβ [280], decrease Aβ levels in the brain. Moreover, AD patients
show decreased plasma sLRP1 levels and increased oxidative damage to sLRP1, reducing its
binding capacity for Aβ. This, in turn, increases the free Aβ fraction in plasma [279], that is,
accessible for RAGE-dependent influx back to the brain [281].
Higher sRAGE levels are linked to reduced risk of developing several disorders such as
cardiovascular disease and AD. Levels of sRAGE are decreased in AD and in vascular
dementia, which may confer a target for therapeutic purposes [282]. It has been demonstrated
that systemic administration of a truncated form of RAGE decreases Aβ load in a transgenic
mouse model [241]. Moreover, sRAGE has an inverse relationship with cholesterol, presenting
another modulatory impact on Aβ metabolism due to the role of cholesterol as a mediator of
inflammation and APP processing [145].
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4.1.2. Alterations in other plasma proteins in AD
Few proteins are synthesized solely by the brain or are present in higher concentrations in CSF
compared with the blood. In conditions of the BBB failure, these CSF markers can appear or
be increased in the plasma [283]. Hence, estimating levels of CSF proteins in the plasma may
be a reliable method to control BBB integrity. For instance, S-100 is primarily produced in the
brain by astrocytes and when the BBB is disturbed it is quickly released from the brain and
appears in the blood [284].
4.2. Liver and Aβ elimination
At the periphery, the liver play important roles not only in the storage and in the release of
nutrients and proteins but also in the neutralization and elimination of a variety of toxic
substances such as Aβ from the plasma.
The receptor for LDL (LDLr), LRP1, and megalin/LRP2 play important roles in endocytosis of
lipoproteins and systemic lipid homeostasis. Moreover, LRP1 mediates the clearance of a
multitude of extracellular ligands such as Aβ and regulates diverse signaling processes such
as growth factor signaling, inflammatory signaling pathways, apoptosis, and phagocytosis in
liver.
In the liver, LRP1, which can be blocked by the receptor-associated protein (RAP), has been
shown to be the predominant transporter that mediates systemic clearance of Aβ [285]. LRP1
localized to hepatic cells binds to and systemically clears circulating Aβ. Reduced hepatic LRP1
levels are associated with decreased peripheral Aβ clearance in aged rats. In aged squirrel
monkeys, systemic clearance of Aβ is also reduced and associated with increased Aβ levels in
the brain. In addition to the liver, sLRP1-Aβ complexes and free Aβ are removed through the
kidneys [279]. Liver was also demonstrated to be the major source of Aβ and to be able to
regulate brain Aβ levels [286].
The half-life of circulating Aβ is short, in the range of minutes [287, 288]. This also suggests
that rapid systemic clearance of Aβ prevents reuptake by RAGE after efflux.
It has been shown that some proteins such as insulin [289] and TTR [290] increase LRP1 levels
in hepatic plasma membrane, and in turn enhance peripheral Aβ clearance. Insulin-degrading
enzyme, a zinc metalloendopeptidase that hydrolyzes numerous peptides, including Aβ [238],
insulin [291] and the AICD, has been purified from several mammalian tissues including liver,
brain and blood cells [292]. Furthermore, experiments in rats demonstrated that after 3.5 min
post-infusion of radiolabelled Aβ into the lateral ventricle, 40% of the injected radioactivity
was already in the blood and urine, and internalized by the liver and the kidneys, indicating
not only a quick clearance mechanism but also the involvement of systemic organs in the
elimination and catabolism of Aβ [293]. Therefore, the capacity of the liver to internalize,
catabolize, and eliminate large doses of Aβ, may explain not only the low plasma Aβ levels
but also its small variation noted with age and disease stages.
In some cases, both parenchymal and non-parenchymal liver cells take up proteins, whereas
in other cases this is done mostly by hepatocytes, as happens for TTR, apoA-I, SAP and Aβ. In
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vivo and in vitro experiments showed that hepatocytes are the main cells involved in Aβ
uptake (about 90%) and in its catabolism [288].
5. Transthyretin
Transthyretin (TTR), formerly called prealbumin due to its electrophoretic characteristics,
located just in front of the albumin band, is a plasma protein secreted mainly by the liver and
choroid plexus (CP) [294]. The name “transthyretin” discloses its dual physiological role as a
carrier for thyroid hormones [295] and retinol, the latter through the binding to retinol-binding
protein (RBP) [296]. TTR was first described in the CSF [297] and shortly after in the plasma
[298].
Although the involvement of TTR in the transport of thyroid hormones and RBP, as well as in
FAP, is very well established, its involvement in neuroprotection is part of a very recent
knowledge and constantly evolving.
5.1. TTR gene structure and expression
TTR is codified by a single copy gene localized in the long arm of chromosome 18 [299]. The
entire nucleotide sequence including the 5′ (transcription initiating site) and the 3′ (untrans‐
lated region) flanking regions was determined [300, 301] and attributed to the region 18q11.2–
q12.1 [302]. The full gene is 7.6 kilobase (kb) long comprising 4 exons and 3 introns [300, 301].
Exon 1 contains 95 basepairs (bp), including 26 bp 5′ untranslated, and codes for a 20 aa residue
leader peptide and aa 1–3 of the mature protein; exon 2 (131 bp), 3 (136 bp), and 4 (253 bp) hold
the coding sequences for aa residues 4–47, 48–92 and 93–127, respectively. The introns (A, B
and C) are 934, 2090 and 3308 bp long, respectively. Introns A and C contain two open reading
frames (orf) of unknown significance [301].
The TTR mRNA spans ~0.7 kb and contains a 5′-untranslated region (26–27 nucleotides), a
coding region (441 nucleotides), and a 3′-untranslated region (145–148 nucleotides) preceding
the poly(A) tail [294, 303]. Human [299], rat [304, 305] and mouse [306] coding regions exhibit
a considerable degree of homology (~85%), suggesting a phylogenetically preserved modu‐
lating role in gene expression.
TTR is predominantly synthesized by the liver where more than 90% of the protein is produced.
The remaining is produced by the CP and the retina. TTR is detected in the fetal blood very
early during development, as soon as eight weeks after conception [307]. TTR plasma concen‐
tration is age dependent, and in healthy newborns, it is about half of that in adults [308, 309].
TTR values vary from 20 to 40 mg/dL. In spite of the low TTR levels in CSF (~2 mg/dL), the CP
is presented as the major site of TTR expression, expressed as a ratio of TTR/mass of tissue,
corresponding to a ~30-fold higher than that found in plasma [310]. TTR represents 20% of the
total CSF proteins [310].
With respect to the regulation of TTR expression, several studies showed that liver and CP
TTR expression are increased in response to sex hormones, as demonstrated in mice [311,
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312]. In rats, hydrocortisone and psychosocial stress are also inducers of TTR in the CP [313].
Others studies indicate that TTR can be expressed by brain cells, for instance in response to
the heat shock factor 1 (HSF1) and to the AICD fragment of APP, as we will discuss further
ahead in the context of TTR protection in AD.
5.2. TTR protein structure
The TTR mRNA codifies for the TTR-monomer; the polypeptide of 147 aa residues whose N-
terminal region is a hydrophobic signal peptide of 20 aa residues. The TTR monomer is
subjected to a cleaving process, during its migration through the ER, giving rise to the native
TTR monomer after breaking of the signal peptide [294]. Assembly of four identical subunits
(13,745 Da) occurs yielding the mature tetrameric protein, with a molecular mass of 54,980 Da
[314].
Figure 2. The human TTR tetrameric structure complexed with two molecules of RBP (light green), which in turn is
bound to retinol, and with T4 (binding in the central channel).
The tridimensional structure of TTR was made available at 1.8 Å resolution by X-ray diffraction
studies on the crystallized protein [315]. Each monomer contains two β-sheets formed by
strands DAGH and CBEF. All, except strands A and G, display an antiparallel orientation, and
are arranged in a topology similar to the classic Greek key barrel. The strands are 7–8 residues
long, except strand D, which, is only 3 residues in length. Only about 5% of the aa residues are
located in one segment of α-helix comprising residues 75–83, at the end of strand E. Two
monomers associate forming the dimer by interactions between chains F and H of each
monomer. Fixing the chains of one monomer as A–H and the ones of the other monomer as A
′–H′, the arrangement within a dimer is DAGHH′G ′A ′D ′ and CBEFF′E ′B ′C ′. The tetramer
consists of two dimers with connecting edges occurring between the AB loop of one dimer
with the H strand of the other dimer (Figure 2). The quaternary structure of TTR has the shape
of a globular protein with an overall size of 70 Å × 55 Å × 50 Å [315]. The two dimers are slightly
rotated in relation to each other along the y axis.
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5.3. Physiology and Metabolism
5.3.1. Transport of thyroxine (T4)
Thyroid hormones are transported in blood circulation and delivered to the target tissues, with
an incredible high amount of the hormones (99%) bound to serum proteins. In human plasma,
TTR, thyroxine-binding protein (TBG) and albumin are responsible for the delivery of T4 into
the target tissues. Although TBG is much less concentrated in the plasma than TTR, it presents
the highest affinity constant for T4 (Ka = 1 × 1010 M−1) and transports about 70% of the plasma
T4. TTR has an intermediate affinity for T4 (Ka = 7 ×  107 M−1) and transports about 15% of the
hormone, and finally, albumin presents the lowest binding affinity (Ka = 7 × 105 M−1) [316].
The four monomers of the TTR tetramer, demarcate an open channel through the molecule
where two binding sites for thyroid hormones are located (Figure 2). These two binding sites
present negative cooperativity [317] implying that when the first thyroid hormone molecule
occupies the first site, the affinity for the second molecule is highly reduced.
T4 transport into the brain is of particular interest and has raised much controversy [318].
Although TTR is the major T4-binding protein in the CSF, studies done in ttr knock-out mice
(TTR−/−) [319] revealed that TTR is not essential for thyroxine to reach the brain and other tissues
[320]. In addition, measurement of several parameters of thyroid hormone function indicates
that these mice are euthyroid despite strongly reduced total T4 plasma levels [321]. No other
protein was found to replace TTR in the transport of T4 in the CSF, and T4 levels were normal
in the cortex, cerebellum, and hippocampus while strongly reduced in the CP of the TTR−/−
mice [322].
Therefore, it was suggested that TTR might be a reservoir for T4 both in the plasma and in the
CP and CSF, which might become important under conditions of increased hormone demand.
5.3.2. Transport of vitamin A
TTR is also responsible for retinol transport through binding to retinol-binding protein (RBP,
Figure 2). RBP is a 21 kDa monomeric protein comprising 182 aa residues [323]. The confor‐
mational structure of RBP bound to retinol was determined by x-ray crystallography [324]. In
most instances, RBP is transported in the bloodstream in the form of a saturated holo-RBP
protein equimolarly attached to TTR [325]. Although TTR has four binding sites for RBP [326,
327], under physiological conditions only one RBP molecule is bound to TTR due to the RBP
limiting concentration.
5.3.3. TTR metabolism
The biological half-life of TTR is about 2–3 days in humans [328, 329], 22–23 h in monkeys [330]
and 10–13 h in rats [331]. The major sites of TTR degradation in the rat are liver (36–38%),
followed by the muscle (12–15%) and skin (8–10%) [332].
The normal physiology of TTR is not completely understood, in particular, its cellular uptake.
Nevertheless, several observations suggest that TTR internalization is receptor-mediated, both
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in human hepatoma cells (HepG2) [333] and in chicken oocytes [334]. Megalin, a receptor
implicated in the renal re-uptake of plasma proteins carriers of lipophilic compounds, was
shown to play a role in renal uptake of TTR [335]. Furthermore, different TTR mutations
presented different levels of cell association and degradation, suggesting that the structure of
TTR is important for megalin recognition. TTR internalization was further explored by
studying TTR uptake using hepatomas and primary hepatocytes [336]. This work showed
direct evidence for TTR internalization by a specific receptor, forming a ~90 kDa complex. TTR
internalization was inhibited by RBP (70% decrease) and T4 (20% decrease) and TTR mutants
revealed differences in uptake, indicating again that the recognition by receptor is structure
dependent. Internalization was also inhibited by lipoproteins and RAP, a ligand for all
members of the low-density lipoprotein receptor family (LDLr). All together, these results
suggest a common pathway for TTR and lipoprotein metabolism and the existence of a RAP-
sensitive receptor for TTR internalization. TTR is also internalized by several other cells types
in cell culture, such as astrocytoma cells [337], cardiomiocytes [338, 339], neurons [340, 341],
endothelial cells and others. More recently, TTR was also shown to be uptaken by sensory
neurons, an event also mediated by megalin [340].
5.3.4. Proteolytic activity
TTR was also found to act as a cryptic protease and the first substrate described was apoA-I
[342, 343]. TTR is also able to cleave lipidated apoA-I (mainly in the lipid poor pre β-HDL
subpopulation) which can be relevant in the lipoprotein metabolism [343]. Moreover, apoA-I
cleaved by TTR presents less ability to promote cholesterol efflux [343] and shows increased
amyloidogenecity and propensity to form aggregates. Liz et al. also described that TTR was
able to cleave amidated neuropeptide Y (NPY) and that its proteolytic activity affects axonal
growth, leading to the conclusion that TTR has natural substrates in the nervous system [344].
Newly, the same authors described TTR as a metallopeptidase [345], and this result was
supported by another study that showed the involvement of a carboxylate and an ammonium
group, possibly from a lysine side chain, in the TTR hydrolytic activity [346]. Costa et al.
showed for the first time that TTR can cleave Aβ peptide in vitro [347] and implications in
Aβ clearance in AD will be addressed further ahead.
5.4. TTR as a cause of disease
TTR is associated with the most prevalent type of hereditary systemic amyloidosis. The
pathologic conditions include FAP and familial amyloidotic cardiomyopathy (FAC). A non-
hereditary condition is also related to TTR, the systemic senile amyloidosis (SSA), and affects
about 25% of people over 80 years of age. In SAA, the deposits occur in the heart and are
composed of wild-type (WT) TTR.
FAP is related to a peculiar form of hereditary autosomal dominant polyneuropathy. Corino
de Andrade first described the disease in 1952 [6] in the Portuguese population mainly from
the northern part of the country. Characterized by systemic deposition of amyloid and with a
special involvement of the peripheral nerves, the age of onset of the disease is usually between
20 and 35 years of age, with a fast progression to death within 10–15 years.
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Clinically, FAP is characterized by early impairment of temperature and pain sensation in the
feet, and autonomic dysfunction leading to paresis, malabsorption, and emaciation. Painless
injury to the feet complicated by ulcers, cellulitis, osteomyelitis, and Charcots joints may also
occur [348]. Motor involvement occurs with disease development causing wasting and
weakness, and there is a progressive loss of reflexes. The amyloid deposits can occur in any
part of the peripheral nervous system, including the nerve trunks, plexus, and sensory and
autonomic ganglia. The other organ frequently involved in FAP, which is the heart. Clinically,
the cardiomyopathy may present as an arrhythmia, heart block, or heat failure.
The first report relating immunologically TTR as the main protein in FAP fibrils was in 1978
by Costa and colleagues [349]. In 1984, the Val30Met mutation was identified in the protein
isolated from Portuguese FAP patients. This variant was shown to be a biochemical marker
for FAP [350] that resulted from a point mutation in the exon 2 of the TTR gene [351]. Since
the identification of the Val30Met variant, many others aa substitutions were identified in the
TTR protein and now over 100 mutations are described (http://amyloidosismutations.com/
mut-attr.php); these variants are associated with different clinical phenotypes and a consid‐
erable number of non-pathogenic TTR mutations have been identified, including a T119M
variant described to be protective.
TTR tetramer dissociation is believed to be on the basis of a series of events leading to TTR
amyloid formation. In fact, the amyloidogenic potential of the TTR variants relates inversely
with its tetrameric stability, and it is thought that upon dissociation of the tetramer, non-native
TTR monomers are formed which can assemble, forming amyloidogenic intermediate species,
such as oligomers and aggregates. Similarly to other amyloidogenic proteins, it is now believed
that cellular toxicity is derived from the initial intermediate species occurring in the initial
stages of FAP [352]. TTR stabilization has been proposed as a key step for the inhibition of TTR
fibril formation and has been the basis for FAP therapeutic strategies. Such stabilization can
be achieved through the use of small compounds sharing molecular structural similarities with
T4 and binding in the T4 central-binding channel. Most of such compounds belong to the class
of NSAIDs as it is the case of diflunisal and tafamidis, currently being administrated to FAP
patients. For instance, in FAP patients, diflunisal was shown to stabilize TTR, increasing its
serum concentration [353], and to reduce the rate of progression of neurological impairment
and to preserve quality of life [354].
6. TTR and neuroprotection
Several lines of evidence indicate that TTR possesses neuroprotective properties in multiple
contexts. Studies with TTR−/− mice revealed that these animals show reduced signs of de‐
pressive-like behavior, probably due to the modulation of noradrenergic system by the in‐
crease of noradrenaline in the limbic forebrain [355]. Additionally, increased levels of NPY,
known as an antidepressant neurotransmitter [356], were reported in dorsal root ganglia
(DRG), sciatic nerve, spinal cord, hippocampus, cortex, and CSF of TTR−/− mice [357], sup‐
porting the importance of TTR in the modulation of depressive behavior. Furthermore,
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Sousa and co-workers also described that TTR−/− mice present memory impairment com‐
pared with wild-type (TTR+/+) animals, indicating that the absence of TTR accelerates cogni‐
tive deficits usually associated with aging [358].
In addition, TTR was associated with nerve regeneration. Fleming et al. revealed, for the
first time, that TTR acts as an enhancer of nerve regeneration, following the observation that
TTR−/− mice have decreased ability to regenerate from a sciatic crushed nerve [359]. Later,
the same authors showed that the absence of TTR leads to impaired retrograde transport
and decreased axonal growth, and also that the effect of TTR in neurite outgrowth and
nerve regeneration is mediated by megalin-dependent internalization [340].
It was also established a relationship between TTR and ischemia, one of the major causes of
brain injuries in world. Santos and co-workers proposed that in a compromised heat-shock
response, CSF TTR contributes to control neuronal cell death, edema, and inflammation,
influencing the survival endangered neurons [360].
More recently, a new neuroprotective role in the CNS was attributed to TTR, as a transcription
inducer of insulin-like growth factor receptor I (IGF-IR), known as a protective receptor against
apoptosis [361]. Vieira and colleagues described, for the first time, that TTR induces increased
levels of IGF-IR, showing that TTR triggers IGF-IR nuclear translocation in cultured neurons
[341].
6.1. TTR protection in Alzheimer’s Disease
There are several reports suggesting a relevant protective role of TTR in AD. However, the
precise mechanism(s) is not entirely understood.
In 1993, Wisniewski described that Aβ40 fibril formation was inhibited upon incubation with
human CSF [362], which was explained by the sequestration of Aβ by extracellular proteins
circulating in CSF such as apoE and apoJ [362–364]. The earliest description of TTR protection
in AD was presented by Schwarzman and colleagues in 1994 when they observed that, in CSF
and contrarily to the expectations, apoE was not the major protein binding to Aβ, but TTR
[365], proposing the sequestration hypothesis as a possible explanation for the peptide
aggregation and consequent progression of AD. This hypothesis suggested that certain
extracellular proteins sequester normally produced Aβ, thereby preventing amyloid formation
and its toxicity. Amyloid formation would occur when sequestration failed [365, 366], which
could be related either with an Aβ overproduction, a reduction in the levels of the sequestering
proteins, inability of those proteins to interact with the peptide, deficient clearance mecha‐
nisms, or a combination of all the events above stated.
Supporting a protective role for TTR in AD are its decreased levels observed both in the CSF
[367] and in the plasma [114, 368] of AD patients as compared to age-matched subjects. Serot
and coworkers suggested that the decrease in TTR levels in the CSF of AD brains was possibly
related with an epithelial atrophy in the CP [367]. Interestingly, very recently, studies in an
AD transgenic mouse model reported CP dysfunction and revealed a specific increase only of
the Aβ42 isoform in epithelial cytosol and in stroma surrounding choroidal capillaries,
accompanied by a thickening of the epithelial basal membrane, greater collagen-IV deposition
Modulating Role of TTR in Aβ Toxicity, from Health to Disease
http://dx.doi.org/10.5772/63194
29
around capillaries in CP that probably restrain solute exchanges, and attenuated expression
of epithelial aquaporin-1 and TTR protein compared to non-transgenic mice [369].
Modulation of Aβ aggregation and toxicity was also investigated in brain vascular smooth
muscle cells, isolated from dogs and AD patients, containing intracytoplasmatic granules of
Aβ produced in the presence of apoE. In this model, TTR was able to rescue the cells from this
accumulation and the positive thioflavin S staining, initially observed, was no longer detected
[370].
Although not fully consensual, several authors reported the presence of TTR in amyloid
plaques both in AD patients [371–373] and in AD transgenic models [372], strengthening a role
for TTR in Aβ deposition and in AD. TTR was also identified as a survival gene, and its
differential overexpression in mice hippocampus was suggested to be responsible for the lack
of neurodegeneration observed in the Tg2576 transgenic mice overexpressing the mutant form
of human amyloid precursor protein with the Swedish mutation (APPSw) [374]. Up-regulation
of TTR and other survival genes was induced by the sAPPα, a neuroprotective fragment
resulting from APP processing by α-secretase [373]. TTR up-regulation was also reported in
situations of exposure of AD transgenic mice to an “enriched environment,” also resulting in
pronounced reductions in cerebral Aβ levels and amyloid deposits, compared to animals
raised under “standard housing“ conditions [375]. Later on, AD transgenic models with
genetic reduction of TTR and/or overexpression of human TTR [372] further showed the ability
of TTR to modulate Aβ aggregation and toxicity. While the overexpression of human TTR
ameliorated AD features in APP transgenic mice [372], the ablation of the mouse TTR gene
resulted in accelerated amyloid deposition and increased Aβ brain levels [372, 376, 377]. In
vitro studies further demonstrated that a direct interaction between TTR and Aβ abrogated
the noxious properties of Aβ oligomers [378].
Animal models, in particular mice models, also provided evidence for a gender-associated
modulation of brain Aβ levels [377] as elevated brain levels of Aβ42 were observed in AD
female mice with only one copy of TTR when compared to female with the two copies of the
TTR gene, while no significant differences were observed in males. Additionally, this work
also indicated that reduced levels of brain testosterone and 17β-estradiol in female mice with
TTR genetic reduction might underlie their increased AD-like neuropathology [377]. Interest‐
ingly, estradiol was found to be decreased in female AD patients when compared to healthy
age and gender-matched controls [114], which in conjunction with TTR regulation by sex
hormones, as already described, can account for TTR lowering in AD and the prevalence of
this disease in women. In fact, plasma TTR levels were found decreased in AD women, as
compared to healthy age- and gender-matched controls, whereas plasma TTR levels in AD
men were not significantly different from their respective controls [114], further confirming
the gender modulation by TTR.
6.1.1. TTR and Aβ interaction
TTR and Aβ binding was initially demonstrated by adding radiolabelled Aβ1-28 synthetic
peptide to human CSF and subsequent analysis by SDS-PAGE [365]. Later on, the TTR/Aβ
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complex was also demonstrated in plasma [379], although the details of the interaction as well
as the effects in Aβ fibrillogenesis and toxicity were not known.
In 2008, Costa and colleagues characterized the TTR/Aβ interaction by competition-binding
assays using synthetic Aβ42, which revealed that the WT TTR binds to different Aβ peptide
species: soluble (with a Kd of 28 ± 5 nM), oligomers, and fibrils [378]. Other studies showed
that TTR drastically decreased the rate of aggregation without affecting the fraction of Aβ in
the aggregate pool and an estimated apparent KS of 2300 M−1 was calculated [380]. These data
support a hypothesis, wherein TTR preferentially binds to aggregated rather than monomeric
Aβ and arrests further growth of the aggregates. Recent work indicates that the intensity of
TTR binding to Aβ peptide is highest for partially aggregated materials and decreased for
freshly prepared or heavily aggregated Aβ, suggesting that TTR binds selectively to soluble
toxic Aβ aggregates [381]. Although Schwarzman and colleagues had shown in 1994 that TTR
is capable of inhibiting Aβ1-28 aggregation [365], Costa and co-workers showed by transmis‐
sion electron microscopy (TEM) analysis that TTR is capable of interfering with Aβ fibrilliza‐
tion, both at inhibiting its aggregation and at disrupting pre-formed Aβ fibrils [378]. Thus, new
and innovative studies are necessary to clarify the details of this interaction.
Another point of controversy refers to the TTR species involved in Aβ binding. Some studies
support that the TTR monomer rather than the tetramer binds more strongly to Aβ [382], and
it is even suggested that while the TTR monomer arrests Aβ aggregate growth, the tetramer
modestly enhances the peptide aggregation [382]. Another study performed using diverse
natural TTR mutants showed that different TTR variants bind differentially to Aβ in the
following manner: T119M>WT>V30M3Y78F>L55P TTR [378], indicating the lower the amyloi‐
dogenic potential of TTR, the stronger the affinity toward the peptide. Since the amyloidogenic
potential correlates inversely with TTR tetrameric stability, authors concluded that the TTR
tetramer is the species binding to Aβ peptide. Previous work had already shown that amyloi‐
dogenic TTR mutants such as L55P and E42G, the only ones able to form TTR amyloid fibrils
at pH 6.8 amongst the forty-seven variants tested, were unable to bind Aβ [383].
Given the above considerations, it is therefore conceivable that mutations of the TTR gene
could alter the TI'R/Aβ sequestration properties. However, the screening study in AD patients
found no correlation between TTR variants and AD [384], and therefore other factors, namely
conformational changes resulting from aging, should be affecting TTR levels and its binding
properties towards Aβ.
Computer-assisted modelling was developed to determine the possible key residues partici‐
pating in the interaction and the data suggested that residues 38–42, Asparagine 62 (E62) and
E66 of each TTR monomer had a central role in the interaction [365]. Later studies have
confirmed that only the residues 38–42 of TTR were important for the interaction [366]. More
recently, Du and Murphy, identified the A strand, in the inner β-sheet of TTR, as well as the
EF helix, as regions of TTR that are involved with Aβ [382] association. New data from the
same group now indicates the involvement of the G strand of TTR with the particular in‐
volvement of L82A and L110A, suggesting that Aβ binding to TTR is mediated through these
bulky hydrophobic leucines [385].
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6.1.2. Effects of TTR stabilization in AD
The decrease in TTR levels in the context of AD is found early in disease development as
indicated by the lower levels also found in plasma TTR in MCI patients [114]. TTR levels
continue to decrease as disease progresses correlating negatively with disease severity, both
in CSF [115] and plasma [114], and with senile plaque burden [386]. Similar results were found
in AD transgenic mice as TTR was decreased as early as 3 months of age [377], well before
amyloid deposition. Mice, however, seem to be able to compensate and female showed
restored TTR levels at the age of 10 months [377].
The reason for TTR decrease is not known, but its tetrameric stability seems to play an
important role. An unstable TTR can result in accelerated clearance, accounting for the lower
levels observed. Further, such instability can also affect the Aβ sequestration properties of TTR.
Supporting this stability hypothesis is the observation that plasma TTR from AD patients
presents impaired ability to carry T4. This also supports that it is the TTR tetramer that binds
Aβ, since T4 binding to TTR implies that the tetramer is assembled. Very interestingly, TTR
genetic stabilization, that is, the presence of the T119M allele, was associated to decreased
cerebrovascular disease and increased life expectancy [387]. In the context of AD, and arguing
in favor of the stability hypothesis is the observation that the TTR/Aβ interaction can be
improved in vitro in the presence of small chemical molecules known to bind to the T4-binding
channel and to stabilize its tetrameric fold [388]. Importantly, in vivo studies using one of such
stabilizer—iododiflunisal, known to be a very potent TTR stabilizer [389] and shown to
improve TTR/Aβ interaction [388]—administrated to AD transgenic mice resulted in amelio‐
ration of AD features such as cognitive function and Aβ brain deposition [390]. In addition,
plasma levels of Aβ42 were decreased upon iododiflunisal administration. These results
opened the possibility for the use of TTR stabilizers in AD therapeutic drug development.
6.1.3. Mechanisms of TTR protection in AD
Aβ sequestration by TTR and other extracellular proteins was the first hypothesis proposed
to explain why CSF is able to inhibit Aβ amyloid formation, implying that, when sequestered,
Aβ cannot aggregate to form amyloid [362, 365]. However, the precise mechanism leading to
final Aβ removal is not yet elucidated.
Following the identification of the TTR proteolytic activity, it was also described that Aβ
peptide is cleaved by TTR, in vitro, with consequent generation of non-amyloidogenic frag‐
ments or fragments with amyloidogenic potential inferior to the full-length peptide [347].
Since clearance of Aβ from the brain can occur via proteolytic degradation of the peptide by
several enzymes, such as neprilysin (NEP), insulin-degrading enzyme (IDE), Endothelin-
converting enzyme (ECE), angiotensin-converting enzyme (ACE), uPA/tPA-plasmin system,
cathepsin D, and matrix metalloendopeptidase 9 [391, 392], lower levels of TTR or inhibition
of its proteolytic activity would result in less Aβ peptide eliminated by the cells, and there‐
fore in its accumulation and amyloid formation. Interestingly, several sites of Aβ cleavage
by TTR are common to several of the proteases mentioned [347]. Further, NEP is known to
cleave not only monomeric but also oligomeric forms of Aβ localized intra and extracellu‐
larly, as determined in vitro and in vivo [393, 394]; similarly, TTR was shown to degrade
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both monomers and aggregates of Aβ in vitro. Nevertheless, Aβ degradation by TTR was
not yet shown in vivo. It is also not known if binding/sequestration of Aβ and its degrada‐
tion by TTR are part of the same mechanism or are independent processes.
In addition to the peptidolytic removal of Aβ, clearance of the peptide from the brain also
occurs via active transport at the BBB and BCSFB, as already discussed. The receptors for Aβ
at the BBB bind Aβ directly, or bind to one of its carrier proteins, and transport it across the
endothelial cell. The first hint pointing to the involvement of TTR in Aβ transport and clearance
came from the analysis of brain and plasma levels of the peptide in mice with different TTR
genetic backgrounds. Results showed that AD transgenic mice with just one copy of TTR had
lower brain and plasma Aβ levels, as compared to animals with two TTR gene copies, raising
the hypothesis that TTR might be involved both in Aβ brain efflux and in its peripheral removal
at the liver. Very recently, it has been showed that TTR promotes Aβ internalization and efflux
in hCMEC/D3 cells, a BBB cellular model widely used. Importantly, TTR stimulated brain-to-
blood Aβ permeability in hCMEC/D3 which in turn can be explained because TTR itself can
only cross the BBB only in the brain-to-blood direction [290, 332]. Thus, TTR can transport
Aβ from, but not into the brain, acting as a neuroprotective molecule.
The presence of TTR in brain areas other than its site of synthesis and secretion—CP and CSF,
respectively—has been already shown. In situations of injury, such as ischemia, TTR was
detected at the local of infarct and shown to derive from CSF TTR [360]. However, other studies
demonstrated TTR synthesis by cortical [395] or hippocampal neurons both in vitro [396], and
in vivo [397] showing that TTR expression in the brain can be regulated [396]. For instance,
Kerridge and colleagues showed that TTR expressed in SH-SY5Y neuroblastoma cell line is
up-regulated by the AICD fragment of amyloid precursor protein (APP), specifically derived
from the APP695 isoform [396]. Induced accumulation of functional AICD resulted in TTR up-
regulation with concomitant Aβ decreased levels. Wang and colleagues reported that TTR
expression in SH-SY5Y cells, primary hippocampal neurons, and the hippocampus of APP23
mice is significantly enhanced by HSF1 [397]. In any case, TTR is available in the brain and
might participate in brain Aβ efflux by promoting BBB permeability to the peptide. It is also
possible that TTR contributes to Aβ clearance from the brain through the BCSFB.
TTR was also able to increase Aβ internalization by hepatocytes prompting TTR as an Aβ
transporter both in the brain and at periphery. Previous work showed that TTR is internalized
by hepatocytes using a RAP-sensitive receptor, which together with the knowledge that as
follows: (1) LRP1 is the main Aβ receptor both at the BBB and at the liver, (2) LRP1 is prefer‐
entially expressed at the basolateral membrane of the endothelial cells of the BBB, and (3) TTR
can only cross the BBB in the brain-to-blood direction, indicates this receptor is involved in
TTR-assisted Aβ transport. So far, it has been shown that mice with TTR genetic ablation
present decrease levels of brain and liver LRP1 and that TTR added to hCMEC/D3 cells results
in increased LRP1 expression. These findings open new perspectives for TTR/LRP-related
therapeutic interventions in AD. However, a direct interaction between LRP1 and TTR is yet
to be demonstrated. TTR has also been suggested to act in a chaperone-like manner by binding
toxic or pretoxic Aβ aggregates in both the intracellular and extracellular environment [372].
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Figure 3. Schematic representation of the proposed mechanisms underlying TTR Protection in AD. (A) In a healthy
individual, TTR binds Aβ peptide in the brain at the CSF promoting its degradation and elimination through the epi‐
thelial cells of the CP. At the BBB, Aβ effluxes through LRP1 to the blood, a process in which TTR also participates. At
the periphery, TTR and other Aβ bindable substances create a peripheral sink avoiding the return of Aβ to the brain,
and transport the peptide to the liver, where it will be internalized by liver LRP1 for final degradation. (B) In AD pa‐
tients, TTR decreased tetrameric stability for yet unknown reasons, and decreased expression due to decreased sex
hormones, result in lower protein levels in the brain and plasma. In turn, this contributes to failure in Aβ sequestra‐
tion, efflux at the BBB, and peripheral transport to the liver. Impaired Aβ transport at the BBB and internalization/
degradation by the liver is aggravated by LRP1 decreased expression, modulated by TTR.
Therefore, more studies are necessary to unravel the mechanism(s) underlying TTR protection
in AD, and to clarify how the hypothesis presented so far fit together (Figure 3).
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